FAKnostics

FAKnostics is a precision medicine biotechnology company focused on developing innovative diagnostics and therapeutics targeting Focal Adhesion Kinase (FAK). The company utilizes a proprietary platform to identify patients most likely to respond to FAK inhibitors, addressing a significant unmet need in the treatment of aggressive solid tumors such as pancreatic and breast cancer. By integrating companion diagnostics with therapeutic development, FAKnostics aims to enhance the efficacy of oncology treatments and streamline clinical trial stratification. Their approach centers on the role of FAK in tumor progression, metastasis, and the fibrotic tumor microenvironment.